VTGN — Vistagen Therapeutics Share News
0.000.00%
Last trade - 00:00- $7.97m
- -$23.76m
- $1.27m
Vistagen Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Brief: Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
Brief: Vistagen Initiates Fasedienol Repeat Dose Study For The Acute Treatment Of Social Anxiety Disorder
Vistagen Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Vistagen Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Vistagen Initiates Palisade-4 Phase 3 Study Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder
Vistagen Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Vistagen Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Vistagen Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Vistagen Broadens PH80 Global Intellectual Property Portfolio With New Patents For The Treatment Of Migraine
Vistagen Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: VistaGen Announces Positive Results From Phase 2A Pilot Study Of PH15
Brief: Vistagen Initiates PALISADE-3 Phase 3 Study Of Fasedienol For Acute Treatment Of Social Anxiety Disorder
Vistagen Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Vistagen Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Vistagen Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Vistagen Receives Notice From European Patent Office Of Intention To Grant Patent For AV-101
U.S. RESEARCH ROUNDUP- Boeing, McDonald's, Quaker Houghton